Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05093387
Title SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Recruitment Withdrawn
Gender female
Phase Phase I
Variant Requirements No
Sponsors Northwestern University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.